Uses
Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage[1].
in vivo
Mirvetuximab soravtansine (IMGN853; 5 mg/kg; i.v.; female severe combined immunodeficient (SCID) mice with patient-derived xenografts) potentiates the antitumor activity of Carboplatin in vivo[1].
References
[1] Ponte JF, et, al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016 Dec;18(12):775-784. DOI:
10.1016/j.neo.2016.11.002
